These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


149 related items for PubMed ID: 2791191

  • 21. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
    Yamauchi T, Kawai Y, Kishi S, Goto N, Urasaki Y, Imamura S, Fukushima T, Yoshida A, Iwasaki H, Tsutani H, Masada M, Ueda T.
    Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
    [Abstract] [Full Text] [Related]

  • 22. [Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine after intraperitoneal administration].
    Noda T, Oku M, Kiyozuka Y, Maruyama M, Adachi S, Akada S, Okamura Y, Ichijo M.
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2929-35. PubMed ID: 3178241
    [Abstract] [Full Text] [Related]

  • 23. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
    Koller-Lucae SK, Suter MJ, Rentsch KM, Schott H, Schwendener RA.
    Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
    [Abstract] [Full Text] [Related]

  • 24. Simultaneous determination of 1-β-d-Arabinofuranosylcytosine and two metabolites, 1-β-d-Arabinofuranosyluracil and 1-β-d-Arabinofuranosylcytosine triphosphate in leukemic cell by HPLC-MS/MS and the application to cell pharmacokinetics.
    Liang D, Wang W, Jiang X, Yin S.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul 01; 962():14-19. PubMed ID: 24880220
    [Abstract] [Full Text] [Related]

  • 25. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI, Biener R, Krailo M, Finklestein J, Ettinger L, Willoughby M, Siegel SE, Holcenberg JS.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [Abstract] [Full Text] [Related]

  • 26. Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
    Ohno R, Hirano M, Yamagata K, Ohara K, Shirakawa S, Hirota Y, Kobayashi M, Yoshikawa S, Mitomo Y, Ikeda Y.
    Cancer Chemother Pharmacol; 1986 Dec 15; 17(2):161-4. PubMed ID: 3719896
    [Abstract] [Full Text] [Related]

  • 27. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Lichtman S, Henderson V, Freeman J, Deere M.
    Cancer Res; 1988 Mar 01; 48(5):1337-42. PubMed ID: 3342412
    [Abstract] [Full Text] [Related]

  • 28. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T, Kawai Y, Goto N, Kishi S, Imamura S, Yoshida A, Urasaki Y, Fukushima T, Iwasaki H, Tsutani H, Masada M, Ueda T.
    Jpn J Cancer Res; 2001 Sep 01; 92(9):975-82. PubMed ID: 11572766
    [Abstract] [Full Text] [Related]

  • 29. [Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
    Tsutsumi H, Kumakawa T, Hirai M, Kikukawa M, Arie Y, Mori M, Kodo H, Nakamura N, Murai Y, Mizutani R.
    Nihon Ronen Igakkai Zasshi; 1995 Mar 01; 32(3):190-4. PubMed ID: 7596061
    [Abstract] [Full Text] [Related]

  • 30. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T.
    Anticancer Res; 2003 Mar 01; 23(6D):5037-42. PubMed ID: 14981964
    [Abstract] [Full Text] [Related]

  • 31. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI, Bernacki RJ, Hui SW, Rustum Y, West CR.
    Cancer Res; 1990 Jul 15; 50(14):4401-6. PubMed ID: 2364392
    [Abstract] [Full Text] [Related]

  • 32. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
    Periclou AP, Avramis VI.
    Cancer Chemother Pharmacol; 1996 Jul 15; 39(1-2):42-50. PubMed ID: 8995498
    [Abstract] [Full Text] [Related]

  • 33. A sensitive and specific radioimmunoassay for 1-beta-D-arabino-furanosylcytosine.
    Shimada N, Ueda T, Yokoshima T, Oh-Ishi J, Oh-oka T.
    Cancer Lett; 1984 Sep 15; 24(2):173-8. PubMed ID: 6478445
    [Abstract] [Full Text] [Related]

  • 34. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M.
    Leukemia; 1987 Sep 15; 1(9):638-43. PubMed ID: 3478543
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes.
    Horber DH, Ottiger C, Schott H, Schwendener RA.
    J Pharm Pharmacol; 1995 Apr 15; 47(4):282-8. PubMed ID: 7791024
    [Abstract] [Full Text] [Related]

  • 36. Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
    Rosowsky A, Kim SH, Ross J, Wick MM.
    J Med Chem; 1982 Feb 15; 25(2):171-8. PubMed ID: 7057424
    [Abstract] [Full Text] [Related]

  • 37. [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
    Ohno R, Kimura K.
    Gan To Kagaku Ryoho; 1988 Apr 15; 15(4 Pt 2-2):1205-8. PubMed ID: 3382195
    [Abstract] [Full Text] [Related]

  • 38. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA, Beardsley GP, Krikorian JG, Mortara RW, Agarwal RP.
    Cancer Res; 1983 Nov 15; 43(11):5190-3. PubMed ID: 6616454
    [Abstract] [Full Text] [Related]

  • 39. A radioimmunoassay method for 1-beta-D-arabinofuranosyluracil using antibodies directed against 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T, Mihara S, Moffatt JG.
    Cancer Res; 1977 Feb 15; 37(2):625-8. PubMed ID: 12864
    [Abstract] [Full Text] [Related]

  • 40. ara-C in plasma and ara-CTP in leukemic cells after subcutaneous injection and continuous intravenous infusion of ara-C in patients with acute nonlymphoblastic leukemia.
    Liliemark JO, Gahrton G, Paul CY, Peterson CO.
    Semin Oncol; 1987 Jun 15; 14(2 Suppl 1):167-71. PubMed ID: 3589691
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 8.